# IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07483567** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- CLDN18.2 Positive
- Primary Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** IBI343,sintilimab,oxaliplatin,S-1
- **DRUG:** sintilimab,oxaliplatin,S-1

## Key facts

- **NCT ID:** NCT07483567
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2030-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483567, "IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07483567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*